Hypertensive crisis-induced electrocardiographic changes: a case series by Farha, Khalid Abou et al.
Case report
Open Access
Hypertensive crisis-induced electrocardiographic changes:
a case series
Khalid Abou Farha
1*, André van Vliet
1, Sjoerd van Marle
1,
Patrick Vrijlandt
1 and Daan Westenbrink
2
Addresses:
1PRA-International, Institute for Clinical Pharmacology, Groningen and Zuidlaren, The Netherlands
2Cardiology Department, University Medical Centre, Groningen, The Netherlands
Email: KAF* - AboufarhaKhalid@PRAIntl.com; AvV - VlietAndrevan@PRAIntl.com; SvM - MarleSjoerdvan@PRAIntl.com;
PV - VrijlandtPatrick@PRAIntl.com; DW - bdwestenbrink@hotmail.com
*Corresponding author
Received: 19 August 2008 Accepted: 9 February 2009 Published: 20 August 2009
Journal of Medical Case Reports 2009, 3:7283 doi: 10.4076/1752-1947-3-7283
This article is available from: http://jmedicalcasereports.com/jmedicalcasereports/article/view/7283
© 2009 Farha et al.; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: Myocardialinjuryisoneofthemostnotoriouscomplicationsofahypertensivecrisis.Key
electrocardiographsignsusedtodetectcardiacinjurysuchasSTsegmentchangesandcardiacarrhythmias
usually indicate acute ongoing end-organ damage. Lack of early signs to predict end-organ damage might
lead to a delay in the initiation of therapy and selection of the incorrect therapeutic strategy.
Case presentation: We describe five cases of tall, hyper acute symmetrical T-waves alone or
accompanied by other electrocardiograph abnormalities in five healthy participants: three women
aged 52, 60 and 62-years and two men aged 49 and 66-years, during a tyramine-monoamine oxidase-
inhibitor interaction, phase I clinical trial. T-wave changes appeared early during the course of the
hypertensive crisis and were attributed to subendocardial ischemia. The changes were transient and
reverted to baseline in parallel with a fall in blood pressure.
Conclusion: Recognition of tall symmetrical T-waves in early phases of hypertensive crisis heralds
commencement of myocardial damage. This calls for prompt medical intervention to avoid an
impending irreversible myocardial injury. It is our belief that these findings will add new insight into
the management of hypertensive crisis and will open avenues of further investigation.
Introduction
A hypertensive crisis (HC), defined as a rapid and
inappropriate intense elevation of blood pressure with or
without a risk of rapid damage to target organs such as the
heart [1-3], is a common presentation to the emergency
department and appears without history of hypertensive
diseases in 23% of cases [4,5].
Although HC is uncommonly encountered in clinical
trial settings, some investigational drug interaction
studies, such as tyramine combined with monoamine
oxidase inhibitors, might trigger HC [1,3,6]. In this
regard, rapid blood pressure (BP) elevation above
180/100 to 110 mmHg [3,5,7] or a sudden increase in
systolic BP by more than 60 mmHg above baseline in
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alarming sign [6].
There are two main subtypes of HC: hypertensive
emergency and hypertensive urgency. Clinical distinction
between both subtypes is important for risk stratification
and initiation of therapy. On the one hand, hypertensive
emergency, characterized by life-threatening end-organ
damage, requires immediate reduction in BP with
parenteral medications. On the other hand, hypertensive
urgency, a less aggressive form without evidence of acute
target organ damage, requires more conservative therapy
aiming to lower BP over a period of hours to days most
commonly using oral medications [1,3,5].
One of the tools used in the diagnostic workup of
hypertensive crisis is the electrocardiogram (ECG). This
might reveal evidence of myocardial ischemia or
infarction, typically T-wave inversion and in more severe
cases, ST segment displacement [1,7-9]. These changes
mirror cardiac injury and indicate a hypertensive
emergency situation and therefore necessitate prompt
medical intervention.
The design of the clinical trial was recommended by the
division of Neurology product of the U.S. Food and Drug
administration (FDA). The clinical study protocol,
amendments and informed consent including statement
of willingness (English and Dutch) were reviewed (from
legal, ethical and medical points of view) and approved
by the independent Ethics Committee, of the foundation
“evaluation of Ethics in biomedical research”,B E B O
Foundation, Assen, the Netherlands. The Committee is
accredited by the central committee on research invol-
ving human subjects and by the Dutch association of
Ethics Committees. The committee is constituted accord-
ing to the Dutch national act on medical- scientific
research in human being, the regulations of the U.S. FDA
as laid down in the code of Federal regulations, 21 GFR,
part 56 (Institutional Review Board) and the ICH
Harmonized Tripartite Guideline E6 on Good Clinical
Practice (ICH-GCP). During the review process and prior
toapprovaloftheclinicalstudydocuments,themembers
of the committee have taken into consideration the
contents of the above mentioned regulations and the
declaration of Helsinki (1964) as amended by the 52
nd
General Assembly, of the World Medical Association
(Edinburgh 2000) and the EU Clinical Trial Directive
2001/ 20/ EC.
All subjects enrolled in this trial provided written
informed consent before participating in any study-related
activity. They were informed about the nature and purpose
of the trial, participation and termination conditions, risk
and benefits.
The study was conducted in our Clinical facility centre
located in the campus of the University Medical Centre,
Groningen, the Netherlands.
Case presentation
The aim of this trial was to evaluate the interaction
between tyramine and both selective and non-selective
MAO inhibitors. Tyramine was administered in an
escalating dose level design of 25 mg ascending up to
and including 800 mg during a period of 10 days. This
tyramine dose escalation design was, however, discon-
tinued on achieving an increase of more than 30 mmHg
in systolic BP (compared with baseline values) on three
successive measurements with a period of five minutes
between measurements.
As previously mentioned, Prior to study initiation written
informed consent was obtained from all participated
subjects, 179 healthy male and female volunteers, aged
40-70 year (inclusive). This was followed by their medical
history being established; complete physical examination,
thorough laboratory investigations and electrocardiograph
assessments including exercise electrocardiography. These
parameters indicated the healthy non-pathologic status
of all participants. At pre-dose time points, baseline
assessments of the participants’ BP values were deter-
mined. After dosing, a regular BP evaluation was
performed at five-minute intervals for a period of two
hours and thereafter four times hourly for a subsequent
period of two hours. Continuous telemetric recording was
performed pre-dose to provide baseline reference values,
and until at least four hours post-dose.
The trial protocol specified that during the course of the
trial, a hypertensive episode of more than 60 mmHg above
predetermined baseline values would imply the use of
intravenous labetalol, an alpha and beta blocking agent.
This was the case in 35 male and female participants. ECGs
and/or telemetric recordings during the hypertensive
episodes were available from 21 out of 35 participants.
In the electrocardiograph records from all 21 patients,
clinically important T-wave changes were observed.
The material used for this report was obtained from five
participants: three women aged 52-years-old to 62-years-
old and two men aged 49 years-old and 66-years-old.
A hypertensive episode with a rapid increase in systolic
BP > 60 mmHg above the baseline value has been
observed after an oral tyramine dose, as low as 100 mg
in the three female participants and as high as 500 mg in
the two male participants.
Parallel with the peak BP, four participants, Patients 1 to 4,
reported rapid onset of an array of angina symptoms.
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skipped beats, warm sensation, abdominal palpitation
and anxiety in Patient 3, severe headache and chest
compression in Patient 2, and throat tightness, palpitation
and severe occipital pain in Patient 4. The other male
participant, Patient 5, reported no complaints during the
paroxysm of BP elevation.
Synchronous with the peak BP levels, telemetric recordings
of all five participants showed obvious T-wave changes.
The T-waves clearly lost their peculiar asymmetry and
became hyper acute, pointed and high amplitude reaching
values of ca. 0.7 mV, 0.65 mV, 0.7 mV and 0.9 mV in leads
II of, respectively, Patients 2, 1, 3 and 4. These values were
2 to 4 times the values obtained at baseline. In the
remaining male patient, Patient 5, where time-matched
12-lead ECG rhythm traces were available, the T-wave
amplitudes were 0.5 mV, 1.2 mV, 1.3 mV and 1 mV,
respectively, in leads II and V3-V5. Again these values were
approximately two times the values seen in the corre-
sponding leads at the baseline time point. All ECG
recording electrodes were remounted at identical loca-
tions. This avoided inconsistency in voltage tracings
obtained at different time points.
In Patient 2, T-wave changes were an isolated event
without any associated abnormal telemetric findings
(Figure 1). In the remaining four participants T-wave
changes were accompanied by other electrocardiograph
abnormalities. Patient 1 demonstrated a 2:1 atrioventri-
cular second degree heart block (A-V block) with a heart
rate of 60 bpm and narrow QRS complexes but with
constant PR and RR intervals between conducted beats
(Figure 2). Patient 3 demonstrated ventricular bigeminy
(Figure 3), while Patient 5 demonstrated a few sudden
cardiac cycles with prolonged PR interval reaching 360 ms,
greater than two times the baseline value, with a heart rate
of 54 bpm (Figure 4). Patient 4 showed an accelerated
idioventricular rhythm (AIVR). This was followed later by
Figure 1. Telemetric recording obtained (at double
standardization, 10 mm = 0.5 mV) from a female patient
depicting tall symmetric T-wave during a paroxysm of
hypertensive crisis compared to baseline (a) and after
normalization of blood pressure (c).
Figure 2. Telemetric recording obtained (at double
standardization, 10 mm = 0.5 mV) from a female patient,
depictingA-Vseconddegreeheartblock(b)duringanepisodeof
hypertensive crisis. Notice the tall symmetric T-wave compared
to baseline (a) and after normalization of blood pressure (c).
Figure 3. Telemetric recording obtained (at normal
standardization, 10 mm = 1 mV) from a female patient,
depicting tall symmetric T-wave seen early in the course of
a hypertensive crisis episode (b) and in parallel with
ventricular bigeminy (c). Recordings a and d demonstrate
normal electrical cardiac activities at pre-dose (before
tyramine administration) and post blood pressure
normalization time points, respectively.
Page 3 of 6
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:7283 http://jmedicalcasereports.com/jmedicalcasereports/article/view/7283evident inferior lead ST-segment depression (Figure 5). All
five participants were promptly treated with labetalol,
given intravenously as an infusion in doses ranging
from 6 to 16.5 mg. Subsequent normalization of BP was
followed byclearing of symptoms inthe four symptomatic
participants and gradual disappearance of associa-
ted electrocardiograph abnormalities including the
A-V block. In the patient with prolonged PR interval, the
PR duration returned to baseline value directly after
labetalol treatment. Given the severe ischemic changes
observed in the telemetric recording of Patient 4, he was
referred to the cardiology care unit of the University
Hospital Groningen. Assessment of serum cardiac enzymes
revealed a Troponin T level of 0.20 mcg/L, i.e. 20 fold the
reference value (<0.01 mcg/L). The patient was subse-
quently admitted to the cardiology care unit with suspected
acute coronary syndrome. Full cardiological investigations
were performed including coronary angiography and the
patient was discharged three days later after confirmation
of a normal cardiac structural and functional profile.
It is noteworthy that inspection of the telemetric record-
ings of two participants, a female patient with A-V block
and the male patient with AIVR, revealed the start of
T-wave changes as BP increased by values more than
25 mmHg above baseline.
Discussion
The extent of clinical and electrocardiographic findings
encountered during the trial were unforeseen. However,
Figure 4. (a) Electrocardiogram recordings obtained (at
normal standardization, 10 mm = 1 mV) from a male patient,
depicting tall symmetric T-wave (seen in V3 to V5) associated
with prolonged PR interval as seen in leads II, III and aVF
(arrows), during a hypertensive crisis episode. (b) Tracings a
and c demonstrate normal electrical cardiac activities at pre-
dose (before tyramine administration) and post blood
pressure normalization time points, respectively.
Figure 5. Telemetric recordings obtained (at normal
standardization, 10 mm = 1 mV) from a male patient,
depicting tall symmetric T-wave seen in the course of
hypertensive crisis (b) and in parallel with accelerated
idioventricular rhythm (c). ST-segment depression (d) is also
noted. Figure 5a and 5e demonstrate telemetric recordings
obtained at pre-dose (before tyramine administration) and
post blood pressure normalization time points, respectively.
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medication and the risk of blood pressure changes, the
trial was conducted under close and continuous medical
observation and monitoring conditions. An adequate and
prompt treatment protocol for cases exceeding pre
specified safety margin was set up in close collaboration
with the intensive care unit of the University Medical
Centre Groningen.
We have illustrated the appearance of symmetrical pointed
tall T-waves with values of 0.65 mV or higher in lead II of
fourparticipantsandatleast1mVinprecordialleadsofone
male participant, early during the course of hypertensive
crisis, with an emerging onset at >25 mmHg elevation of
systolicBPintwoparticipants,i.e.beforereachingvaluesthat
would normally be denoted as hypertensive crisis. This was
associated with angina symptoms in four participants, and
followed by characteristic electrocardiograph changes that
resolved after labetalol-induced normalization of BP.
Typically, T-waves in healthy patients have non-pointed
smooth asymmetric profiles with amplitudes that are age,
sex and ECG lead dependent. In healthy male and female
patients aged 40 to 60-years, average T-wave amplitudes of
0.23mV and 0.21mV, respectively, have been described in
lead II of the ECG recording [10].
InleadsV3throughV5ofmalepatientsaged40to60-years,
referenceaverageT-waveamplitudesof0.6mV,0.54mVand
0.39 mV have been described [10]. Loss of asymmetrical
T-wave profile with increased amplitude is suspicious,
especially for patients older than 40 years [11]. In this
regard, hyperkalemia, myocardial ischemia and cerebrovas-
cularaccidents have allbeenimplicatedinthe etiology[10].
Our findings can be clarified by the fact that HC causes
asuddenincreaseintheafterloadontheheart.Thisleadsto
an increase in the myocardial workload and myocardial
oxygendemandtherebycausingmyocardial ischemia[12].
In the very early phases of myocardial ischemia, the first
area to be affected is the subendocardium, being farthest
from the blood supply [10,12,13]. This leads to a delay in
the subendocardial recovery time probably due to activa-
tion of the ATP-sensitive K channels [13] that appears
electrocardiographically as tall hyper acute T-waves. At
the same time, prolonged ventricular sub-endocardial
recovery explains the associated cardiac arrhythmias
observed in two participants. This point is crucial in
planning a therapeutic strategy for HC cases, since tall
T-wavesappearintheearlyreversibleischemicphasebefore
myocardial injury occurs. In this context, the clinical
significance of T-wave changes is underlined in the HC
situation seen in patients with diabetes mellitus who suffer
cardiac autonomic neuropathy and lack typical angina
symptoms. An appropriate treatment with parenteral first
line medications such as labetalol in this early reversible
phase might be an end-organ salvage measure.
Interestingly, one male patient demonstrated a prolonged
PR interval while, in one female patient, a 2:1 second
degree A-V block was observed during the hypertensive
episode. The association of the A-V block with HC,
symmetrical tall T-waves and the absence of bradycardia
indicates ischemic rather than vagally induced heart block
as an underlying mechanism. Treating both participants
with labetalol led to normalization of BP and was
followed by resolution of the A-V block profile and
reduction in the associated symptoms in the female
patient. The relationship between myocardial ischemia
and A-V block including a 2:1 second degree heart block
has been previously reported [14].
The central role of myocardial ischemia in the patho-
genesis of A-V block seen during HC should, therefore, be
considered in the therapeutic approach to non-vagally
induced A-V block.
Finally, three points are worth mentioning. First, most of
our findings were noted in telemetric records. This
facilitates detailed tracing of cardiac electrical activity
changes occurring during the hypertensive episodes.
Compared to the routine 12-lead ECG tracing, telemetric
recordings appear technically a more time sparing
procedure, requiring less frequent electrode mounting. In
addition, it is a more informative tool, in detecting early
cardiac electrical changes associated with HC, given the
fact that cardiac electric activity can be displayed on
a continuous basis. Therefore, we believe that, in the
HC situation, the use of a telemetric recording or bedside
monitoring is superior to ECG tracing in risk stratification
and thence, offers a timely targeting of a successful
treatment strategy. Second, this study is based on
incidental observations during a phase I clinical trial.
Accordingly, verification of these unforeseen findings with
other supplemental investigational tests such as cardiac
markers was not scheduled and was not done on any
participant except for Patient 4. Further investigations to
explore the clinical significance of T-wave changes in HC
are, therefore, still warranted. Lastly, the trial gives a sound
signal and a clear warning sign to the serious risk of cardiac
damage during hypertensive crises. Still worthy of notice,
the observeduntoward cardiovascular effect resulting from
Tyramine administration in supra physiologic escalating
doses. This should raise the question whether Tyramine
administration in ascending doses could be justified in
future clinical trials.
Conclusions
An asymmetric tall T-wave is an important early ECG
myocardial ischemic sign which should not be overlooked
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non-drug-related hypertensive crisis. Recognition of
T-wave abnormalities should facilitate rapid and appro-
priate interventions that might abort the cascade of
progressive cardiac damage. In the setting of hypertensive
crisis, an A-V block associated with an asymmetric tall
T-wave, particularly in the absence of bradycardia, should
draw attention to the ischemic nature of the disorder
which usually requires controlling of BP by parenteral first
line medication.
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